Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

September 10, 2019

Study Completion Date

September 10, 2019

Conditions
High Risk Smoldering Multiple Myeloma
Interventions
DRUG

Ibrutinib

"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER